Download Pulmozyme with the PARI eRapid Nebulizer System

Now approved:
Pulmozyme with the PARI eRapid™ Nebulizer System
For more information on the
eRapid Nebulizer System,
call PARI at
(866) 335-6943
Since its approval in 1993,1 Pulmozyme has been a cornerstone of cystic fibrosis
(CF) therapy.2 We would like to announce that Pulmozyme has been approved for use with
the eRapid Nebulizer System, which delivers short treatment times.*3
What is the eRapid Nebulizer System?
n The eRapid Nebulizer System is a general-purpose electronic nebulizer that is able to deliver aerosolized medications
n A phase IV study was done to evaluate comparable efficacy and safety of the PARI eRapid Nebulizer System,
which is now a part of the approved list of nebulizers that deliver Pulmozyme treatments
n The eRapid Nebulizer System is small, portable, quiet, and quick*4,5
Approved nebulizers and compressors
Jet Nebulizers
Compressors
Hudson T Up-draft II with
Marquest Acorn II® with
PARI LC® Plus with
†
PARI BABY™ with
Durable Sidestream® with
Durable Sidestream® with
Nebulizer System
PARI eRapid™ Nebulizer System‡
®
Pulmo-Aide®
Pulmo-Aide®
PARI PRONEB®
PARI PRONEB®
MOBILAIRE™
Porta-Neb®
Genentech continues to help fight CF
After 20 years, Genentech is still committed to
helping CF patients with Pulmozyme1,2
Coverage and reimbursement
n Gaining access to the eRapid Nebulizer System may involve reimbursement challenges and the eRapid Nebulizer System may not be approved by many payers.
Patients who have coverage may encounter significant out-of-pocket costs and patients who do not have coverage may expect to pay full retail price
n For more information on the eRapid Nebulizer System, call PARI at (866) 335-6943 or visit www.pari.com
n For more information on Pulmozyme, talk to your local Genentech representative
*The average nebulization time for the eRapid Nebulizer System is approximately 2-3 minutes compared to the LC® Plus Jet Nebulizer, which is 6-10 minutes.4,5
INDICATION
Pulmozyme (dornase alfa) is indicated for daily administration in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.
In CF patients with an FVC ≥40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
IMPORTANT SAFETY INFORMATION
n Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product
n The most common adverse reactions associated with the use of Pulmozyme include: voice alteration, pharyngitis, rash, laryngitis, chest pain, conjunctivitis, rhinitis, decrease in FVC of
≥10%, fever, dyspepsia, and dyspnea. There have been no reports of anaphylaxis attributed to the administration of Pulmozyme. Mild to moderate urticaria and mild skin rash have been
observed and have been transient
eRapid is a trademark of PARI Pharma GmbH. PARI LC PLUS and PRONEB are registered trademarks and PARI BABY is a trademark of PARI Respiratory Equipment, Inc. Up-draft II is a registered trademark
of Teleflex Medical Incorporated Corporation. Acorn and Portaneb are registered trademarks of Medic-Aide Limited. Pulmo-Aide is a registered trademark of DeVilbiss Healthcare LLC. Sidestream is a registered
trademark of Respironics (UK) Ltd. MOBILAIRE is a trademark of Invacare Corporation.
Please see accompanying full Pulmozyme Prescribing Information for additional important safety information.
References: 1. Cystic Fibrosis Foundation. Pulmozyme Inhalation Solution. www.cff.org/treatments/therapies/respiratory/pulmozyme. Accessed November 21, 2014. 2. Cystic Fibrosis Foundation Patient Registry: 2012
Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation; 2013. 3. Naehrig S, Lang S, Schiffl H, et al. Lung function in adult patients with cystic fibrosis after using the eFlow® rapid for one year. Eur J Med Res.
2011;16(2):63-66. 4. Scherer T, Geller DE, Owyang L, et al. A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J Pharm Sci.
2011;100(1):98-109. 5. Data on file. Genentech, a member of the Roche Group.
© 2014 Genentech USA, Inc., So. San Francisco, CA
PUL/103114/0016
12/14